

environment. This document presents statements of findings made by EPA during the period from February 1, 2022 to February 28, 2022.

### III. What is the Agency's authority for taking this action?

TSCA section 5(a)(3) requires EPA to review a TSCA section 5(a) notice and make one of the following specific findings:

- The chemical substance or significant new use presents an unreasonable risk of injury to health or the environment;
- The information available to EPA is insufficient to permit a reasoned evaluation of the health and environmental effects of the chemical substance or significant new use;
- The information available to EPA is insufficient to permit a reasoned evaluation of the health and environmental effects and the chemical substance or significant new use may present an unreasonable risk of injury to health or the environment;
- The chemical substance is or will be produced in substantial quantities, and such substance either enters or may reasonably be anticipated to enter the environment in substantial quantities or there is or may be significant or substantial human exposure to the substance; or
- The chemical substance or significant new use is not likely to

present an unreasonable risk of injury to health or the environment.

Unreasonable risk findings must be made without consideration of costs or other non-risk factors, including an unreasonable risk to a potentially exposed or susceptible subpopulation identified as relevant under the conditions of use. The term "conditions of use" is defined in TSCA section 3 to mean "the circumstances, as determined by the Administrator, under which a chemical substance is intended, known, or reasonably foreseen to be manufactured, processed, distributed in commerce, used, or disposed of."

EPA is required under TSCA section 5(g) to publish in the **Federal Register** a statement of its findings after its review of a TSCA section 5(a) notice when EPA makes a finding that a new chemical substance or significant new use is not likely to present an unreasonable risk of injury to health or the environment. Such statements apply to PMNs, MCANs, and SNUNs submitted to EPA under TSCA section 5.

Anyone who plans to manufacture (which includes import) a new chemical substance for a non-exempt commercial purpose and any manufacturer or processor wishing to engage in a use of a chemical substance designated by EPA as a significant new use must submit a notice to EPA at least 90 days before

commencing manufacture of the new chemical substance or before engaging in the significant new use.

The submitter of a notice to EPA for which EPA has made a finding of "not likely to present an unreasonable risk of injury to health or the environment" may commence manufacture of the chemical substance or manufacture or processing for the significant new use notwithstanding any remaining portion of the applicable review period.

### IV. Statements of Administrator Findings Under TSCA Section 5(a)(3)(C)

In this unit, EPA provides the following information (to the extent that such information is not claimed as Confidential Business Information (CBI)) on the PMNs, MCANs and SNUNs for which, during this period, EPA has made findings under TSCA section 5(a)(3)(C) that the new chemical substances or significant new uses are not likely to present an unreasonable risk of injury to health or the environment:

- EPA case number assigned to the TSCA section 5(a) notice.
- Chemical identity (generic name if the specific name is claimed as CBI).
- Website link to EPA's decision document describing the basis of the "not likely to present an unreasonable risk" finding made by EPA under TSCA section 5(a)(3)(C).

EPA case No.	Chemical identity	Website link
J-22-0008 .....	Modified Yeast (generic)	<a href="https://www.epa.gov/system/files/documents/2022-03/j-22-0008_determination_non-cbi_final.pdf">https://www.epa.gov/system/files/documents/2022-03/j-22-0008_determination_non-cbi_final.pdf</a>

(Authority: 15 U.S.C. 2601 *et seq.*)

Dated: May 6, 2022.

**Madison Le,**

Director, New Chemicals Division, Office of Pollution Prevention and Toxics.

[FR Doc. 2022-10188 Filed 5-11-22; 8:45 am]

BILLING CODE 6560-50-P

### FEDERAL ACCOUNTING STANDARDS ADVISORY BOARD

#### Notice of Request for Comment on an Exposure Draft, Omnibus Amendments: Technical Clarifications Addressing Lessee and Lessor Discount Rates and Sale-Leasebacks

**AGENCY:** Federal Accounting Standards Advisory Board.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Federal Accounting Standards Advisory Board (FASAB) has issued an exposure draft of a proposed Statement

of Federal Financial Accounting Standards titled *Omnibus Amendments: Technical Clarifications Addressing Lessee and Lessor Discount Rates and Sale-leasebacks*. Respondents are encouraged to comment on any part of the exposure draft. Written comments are requested by July 8, 2022, and should be sent to [fasab@fasab.gov](mailto:fasab@fasab.gov) or Monica R. Valentine, Executive Director, Federal Accounting Standards Advisory Board, 441 G Street NW, Suite 1155, Washington, DC 20548.

**ADDRESSES:** The exposure draft is available on the FASAB website at <https://www.fasab.gov/documents-for-comment/>. Copies can be obtained by contacting FASAB at (202) 512-7350.

**FOR FURTHER INFORMATION CONTACT:** Ms. Monica R. Valentine, Executive Director, 441 G Street NW, Suite 1155, Washington, DC 20548, or call (202) 512-7350.

**Authority:** 31 U.S.C. 3511(d), Federal Advisory Committee Act, as amended (5 U.S.C. App.).

Dated: May 9, 2022.

**Monica R. Valentine,**  
Executive Director.

[FR Doc. 2022-10203 Filed 5-11-22; 8:45 am]

BILLING CODE P

### FEDERAL MINE SAFETY AND HEALTH REVIEW COMMISSION

#### Sunshine Act Meetings; Cancellation

May 10, 2022.

The following Commission meeting has been cancelled. No earlier announcement of the cancellation was possible. A Commission meeting in this matter will be rescheduled.

**TIME AND DATE:** 10:00 a.m., Friday, May 13, 2022.

**PLACE:** The Richard V. Backley, Hearing Room, Room 511, 1331 Pennsylvania Avenue NW, Suite 504 North, Washington, DC 20004 (enter from F Street entrance).

**STATUS:** Open.